NBT Bank N A NY Sells 1,434 Shares of Zimmer Biomet Holdings, Inc. $ZBH

NBT Bank N A NY lessened its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 31.3% during the 2nd quarter, HoldingsChannel reports. The firm owned 3,148 shares of the medical equipment provider’s stock after selling 1,434 shares during the period. NBT Bank N A NY’s holdings in Zimmer Biomet were worth $287,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of ZBH. Garde Capital Inc. bought a new stake in Zimmer Biomet in the first quarter worth $29,000. Washington Trust Advisors Inc. bought a new position in Zimmer Biomet during the first quarter valued at $30,000. Columbia River Financial Group LLC bought a new position in Zimmer Biomet during the first quarter valued at $30,000. Accent Capital Management LLC bought a new position in Zimmer Biomet during the first quarter valued at $35,000. Finally, Cullen Frost Bankers Inc. increased its position in Zimmer Biomet by 1,452.4% during the first quarter. Cullen Frost Bankers Inc. now owns 326 shares of the medical equipment provider’s stock valued at $37,000 after acquiring an additional 305 shares during the last quarter. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

ZBH opened at $97.38 on Friday. Zimmer Biomet Holdings, Inc. has a 52-week low of $89.22 and a 52-week high of $114.72. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54. The company has a market cap of $19.29 billion, a P/E ratio of 23.69, a price-to-earnings-growth ratio of 2.26 and a beta of 0.67. The firm’s 50-day moving average price is $101.22 and its 200-day moving average price is $98.44.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The firm had revenue of $2.08 billion for the quarter, compared to the consensus estimate of $2.06 billion. During the same quarter in the prior year, the company posted $2.01 earnings per share. The company’s revenue for the quarter was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be given a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.0%. The ex-dividend date is Tuesday, September 30th. Zimmer Biomet’s dividend payout ratio is currently 23.36%.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the company’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the sale, the senior vice president owned 6,833 shares in the company, valued at approximately $711,656.95. This represents a 18.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 1.39% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on ZBH shares. UBS Group boosted their price objective on shares of Zimmer Biomet from $91.00 to $96.00 and gave the company a “sell” rating in a research report on Friday, August 8th. Redburn Partners set a $130.00 target price on shares of Zimmer Biomet in a research note on Thursday, September 18th. Rothschild Redb raised shares of Zimmer Biomet to a “strong-buy” rating in a research note on Thursday, September 18th. Rothschild & Co Redburn initiated coverage on shares of Zimmer Biomet in a research note on Thursday, September 18th. They issued a “buy” rating and a $130.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zimmer Biomet in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Zimmer Biomet has a consensus rating of “Hold” and an average target price of $112.89.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.